Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230


Use of a whole-cell ELISA to detect additional antibodies in setting of suspected heparin-induced thrombocytopenia.

Bashover EM, Stefaniuk CM, Harding CV, Maitta RW.

Eur J Haematol. 2019 Aug;103(2):99-106. doi: 10.1111/ejh.13263. Epub 2019 Jun 13.


Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA.

Chen L, Feng Z, Yue H, Bazdar D, Mbonye U, Zender C, Harding CV, Bruggeman L, Karn J, Sieg SF, Wang B, Jin G.

Nat Commun. 2018 Nov 2;9(1):4585. doi: 10.1038/s41467-018-07006-2.


Ultrastructural changes in peripheral blood leukocytes in α-synuclein knockout mice.

Tashkandi H, Shameli A, Harding CV, Maitta RW.

Blood Cells Mol Dis. 2018 Nov;73:33-37. doi: 10.1016/j.bcmd.2018.09.001. Epub 2018 Sep 1.


α-Synuclein concentration increases over time in plasma supernatant of single donor platelets.

Stefaniuk CM, Hong H, Harding CV, Maitta RW.

Eur J Haematol. 2018 Jul 28. doi: 10.1111/ejh.13152. [Epub ahead of print]


Mycobacterium tuberculosis Lipoprotein and Lipoglycan Binding to Toll-Like Receptor 2 Correlates with Agonist Activity and Functional Outcomes.

Shukla S, Richardson ET, Drage MG, Boom WH, Harding CV.

Infect Immun. 2018 Sep 21;86(10). pii: e00450-18. doi: 10.1128/IAI.00450-18. Print 2018 Oct.


In Reply to Sun et al.

Harding CV, Akabas MH, Andersen OS.

Acad Med. 2018 Feb;93(2):150-151. doi: 10.1097/ACM.0000000000002036. No abstract available.


Proteomics and Network Analyses Reveal Inhibition of Akt-mTOR Signaling in CD4+ T Cells by Mycobacterium tuberculosis Mannose-Capped Lipoarabinomannan.

Karim AF, Sande OJ, Tomechko SE, Ding X, Li M, Maxwell S, Ewing RM, Harding CV, Rojas RE, Chance MR, Boom WH.

Proteomics. 2017 Nov;17(22). doi: 10.1002/pmic.201700233.


History and Outcomes of 50 Years of Physician-Scientist Training in Medical Scientist Training Programs.

Harding CV, Akabas MH, Andersen OS.

Acad Med. 2017 Oct;92(10):1390-1398. doi: 10.1097/ACM.0000000000001779.


Mycobacterium tuberculosis Membrane Vesicles Inhibit T Cell Activation.

Athman JJ, Sande OJ, Groft SG, Reba SM, Nagy N, Wearsch PA, Richardson ET, Rojas R, Boom WH, Shukla S, Harding CV.

J Immunol. 2017 Mar 1;198(5):2028-2037. doi: 10.4049/jimmunol.1601199. Epub 2017 Jan 25.


A rapid, automated surface protein profiling of single circulating exosomes in human blood.

Kibria G, Ramos EK, Lee KE, Bedoyan S, Huang S, Samaeekia R, Athman JJ, Harding CV, Lötvall J, Harris L, Thompson CL, Liu H.

Sci Rep. 2016 Nov 7;6:36502. doi: 10.1038/srep36502.


Responsiveness to IL-7 but not to IFN-α is diminished in CD4+ T cells from treated HIV infected patients who experience poor CD4+ T-cell recovery.

Nguyen TP, Shukla S, Asaad R, Freeman ML, Lederman MM, Harding CV, Sieg SF.

AIDS. 2016 Aug 24;30(13):2033-42. doi: 10.1097/QAD.0000000000001161.


Extracellular vesicles and infectious diseases: new complexity to an old story.

Schorey JS, Harding CV.

J Clin Invest. 2016 Apr 1;126(4):1181-9. doi: 10.1172/JCI81132. Epub 2016 Apr 1. Review.


Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis Induces CD4+ T Cell Anergy via GRAIL.

Sande OJ, Karim AF, Li Q, Ding X, Harding CV, Rojas RE, Boom WH.

J Immunol. 2016 Jan 15;196(2):691-702. doi: 10.4049/jimmunol.1500710. Epub 2015 Dec 14.


A critical role for alpha-synuclein in development and function of T lymphocytes.

Shameli A, Xiao W, Zheng Y, Shyu S, Sumodi J, Meyerson HJ, Harding CV, Maitta RW.

Immunobiology. 2016 Feb;221(2):333-40. doi: 10.1016/j.imbio.2015.10.002. Epub 2015 Oct 20.


ERK Signaling Is Essential for Macrophage Development.

Richardson ET, Shukla S, Nagy N, Boom WH, Beck RC, Zhou L, Landreth GE, Harding CV.

PLoS One. 2015 Oct 7;10(10):e0140064. doi: 10.1371/journal.pone.0140064. eCollection 2015.


Bacterial Membrane Vesicles Mediate the Release of Mycobacterium tuberculosis Lipoglycans and Lipoproteins from Infected Macrophages.

Athman JJ, Wang Y, McDonald DJ, Boom WH, Harding CV, Wearsch PA.

J Immunol. 2015 Aug 1;195(3):1044-53. doi: 10.4049/jimmunol.1402894. Epub 2015 Jun 24.


Interferon-α inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling.

Nguyen TP, Bazdar DA, Mudd JC, Lederman MM, Harding CV, Hardy GA, Sieg SF.

J Leukoc Biol. 2015 Jun;97(6):1139-46. doi: 10.1189/jlb.4A0714-345RR. Epub 2015 Mar 17.


Toll-like receptor 2-dependent extracellular signal-regulated kinase signaling in Mycobacterium tuberculosis-infected macrophages drives anti-inflammatory responses and inhibits Th1 polarization of responding T cells.

Richardson ET, Shukla S, Sweet DR, Wearsch PA, Tsichlis PN, Boom WH, Harding CV.

Infect Immun. 2015 Jun;83(6):2242-54. doi: 10.1128/IAI.00135-15. Epub 2015 Mar 16.


Novel quorum-quenching agents promote methicillin-resistant Staphylococcus aureus (MRSA) wound healing and sensitize MRSA to β-lactam antibiotics.

Kuo D, Yu G, Hoch W, Gabay D, Long L, Ghannoum M, Nagy N, Harding CV, Viswanathan R, Shoham M.

Antimicrob Agents Chemother. 2015 Mar;59(3):1512-8. doi: 10.1128/AAC.04767-14. Epub 2014 Dec 22.


Mycobacterium tuberculosis lipoprotein LprG binds lipoarabinomannan and determines its cell envelope localization to control phagolysosomal fusion.

Shukla S, Richardson ET, Athman JJ, Shi L, Wearsch PA, McDonald D, Banaei N, Boom WH, Jackson M, Harding CV.

PLoS Pathog. 2014 Oct 30;10(10):e1004471. doi: 10.1371/journal.ppat.1004471. eCollection 2014 Oct. Erratum in: PLoS Pathog. 2014 Dec;10(12):e1004596.


Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.

Xiao W, Shameli A, Harding CV, Meyerson HJ, Maitta RW.

Immunobiology. 2014 Nov;219(11):836-44. doi: 10.1016/j.imbio.2014.07.014. Epub 2014 Jul 22.


Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis.

Zhang L, Luo Z, Sieg SF, Funderburg NT, Yu X, Fu P, Wu H, Jiao Y, Gao Y, Greenspan NS, Harding CV, Kilby JM, Li Z, Lederman MM, Jiang W.

J Virol. 2014 Oct;88(19):11430-41. doi: 10.1128/JVI.00682-14. Epub 2014 Jul 23.


MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases.

Yu M, Zhou H, Zhao J, Xiao N, Roychowdhury S, Schmitt D, Hu B, Ransohoff RM, Harding CV, Hise AG, Hazen SL, DeFranco AL, Fox PL, Morton RE, Dicorleto PE, Febbraio M, Nagy LE, Smith JD, Wang JA, Li X.

J Exp Med. 2014 May 5;211(5):887-907. doi: 10.1084/jem.20131314. Epub 2014 Apr 21. Erratum in: J Exp Med. 2014 May 5;211(5):1003. Ransohoff, Richard M [added].


TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis.

Reba SM, Li Q, Onwuzulike S, Ding X, Karim AF, Hernandez Y, Fulton SA, Harding CV, Lancioni CL, Nagy N, Rodriguez ME, Wearsch PA, Rojas RE.

Eur J Immunol. 2014 May;44(5):1410-21. doi: 10.1002/eji.201344100. Epub 2014 Mar 14.


Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.

Gabrilovich MI, Walrath J, van Lunteren J, Nethery D, Seifu M, Kern JA, Harding CV, Tuscano L, Lee H, Williams SD, Mackay W, Tomashefski JF Jr, Silver RF.

Clin Exp Immunol. 2013 Sep;173(3):512-22. doi: 10.1111/cei.12138.


Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation.

Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz-Hoover J, Harding CV, Fu P, Katz JA, Lederman MM, Levine AD.

Immunology. 2013 Sep;140(1):87-97. doi: 10.1111/imm.12114.


Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers.

Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, Harding CV.

PLoS One. 2013;8(2):e56527. doi: 10.1371/journal.pone.0056527. Epub 2013 Feb 20.


Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes.

Mudd JC, Murphy P, Manion M, Debernardo R, Hardacre J, Ammori J, Hardy GA, Harding CV, Mahabaleshwar GH, Jain MK, Jacobson JM, Brooks AD, Lewis S, Schacker TW, Anderson J, Haddad EK, Cubas RA, Rodriguez B, Sieg SF, Lederman MM.

Blood. 2013 Apr 11;121(15):2914-22. doi: 10.1182/blood-2012-07-445783. Epub 2013 Feb 19.


Exosomes: looking back three decades and into the future.

Harding CV, Heuser JE, Stahl PD.

J Cell Biol. 2013 Feb 18;200(4):367-71. doi: 10.1083/jcb.201212113. Erratum in: J Cell Biol. 2013 Apr 29;201(3):485.


Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation.

Mahon RN, Sande OJ, Rojas RE, Levine AD, Harding CV, Boom WH.

Cell Immunol. 2012 Jan-Feb;275(1-2):98-105. doi: 10.1016/j.cellimm.2012.02.009. Epub 2012 Mar 14.


Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.

Simmons DP, Wearsch PA, Canaday DH, Meyerson HJ, Liu YC, Wang Y, Boom WH, Harding CV.

J Immunol. 2012 Apr 1;188(7):3116-26. doi: 10.4049/jimmunol.1101313. Epub 2012 Feb 27.


Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline.

Conry SJ, Meng Q, Hardy G, Yonkers NL, Sugalski JM, Hirsch A, Davitkov P, Compan A, Falck-Ytter Y, Blanton RE, Rodriguez B, Harding CV, Anthony DD.

J Infect Dis. 2012 Apr 1;205(7):1131-41. doi: 10.1093/infdis/jis027. Epub 2012 Feb 20.


Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT, Pollard R, Asmuth D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM.

PLoS One. 2012;7(1):e30306. doi: 10.1371/journal.pone.0030306. Epub 2012 Jan 24.


TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9.

Liu YC, Simmons DP, Li X, Abbott DW, Boom WH, Harding CV.

J Immunol. 2012 Feb 1;188(3):1019-26. doi: 10.4049/jimmunol.1102181. Epub 2012 Jan 6.


Rv2468c, a novel Mycobacterium tuberculosis protein that costimulates human CD4+ T cells through VLA-5.

Li Q, Ding X, Thomas JJ, Harding CV, Pecora ND, Ziady AG, Shank S, Boom WH, Lancioni CL, Rojas RE.

J Leukoc Biol. 2012 Feb;91(2):311-20. doi: 10.1189/jlb.0711364. Epub 2011 Dec 7.


Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.

Jiang W, Lederman MM, Harding CV, Sieg SF.

J Immunol. 2011 Feb 15;186(4):2080-6. doi: 10.4049/jimmunol.1001869. Epub 2011 Jan 14.


Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2.

Lancioni CL, Li Q, Thomas JJ, Ding X, Thiel B, Drage MG, Pecora ND, Ziady AG, Shank S, Harding CV, Boom WH, Rojas RE.

Infect Immun. 2011 Feb;79(2):663-73. doi: 10.1128/IAI.00806-10. Epub 2010 Nov 15.


Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation.

Ramachandra L, Qu Y, Wang Y, Lewis CJ, Cobb BA, Takatsu K, Boom WH, Dubyak GR, Harding CV.

Infect Immun. 2010 Dec;78(12):5116-25. doi: 10.1128/IAI.01089-09. Epub 2010 Sep 13.


Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2.

Drage MG, Tsai HC, Pecora ND, Cheng TY, Arida AR, Shukla S, Rojas RE, Seshadri C, Moody DB, Boom WH, Sacchettini JC, Harding CV.

Nat Struct Mol Biol. 2010 Sep;17(9):1088-95. doi: 10.1038/nsmb.1869. Epub 2010 Aug 8.


Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.

Simmons DP, Canaday DH, Liu Y, Li Q, Huang A, Boom WH, Harding CV.

J Immunol. 2010 Aug 15;185(4):2405-15. doi: 10.4049/jimmunol.0904005. Epub 2010 Jul 21.


Mycobacterium tuberculosis promotes HIV trans-infection and suppresses major histocompatibility complex class II antigen processing by dendritic cells.

Reuter MA, Pecora ND, Harding CV, Canaday DH, McDonald D.

J Virol. 2010 Sep;84(17):8549-60. doi: 10.1128/JVI.02303-09. Epub 2010 Jun 30.


Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional vitamin D receptor signalling.

Shin DM, Yuk JM, Lee HM, Lee SH, Son JW, Harding CV, Kim JM, Modlin RL, Jo EK.

Cell Microbiol. 2010 Nov;12(11):1648-65. doi: 10.1111/j.1462-5822.2010.01497.x. Epub 2010 Jul 20.


Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors.

Harding CV, Boom WH.

Nat Rev Microbiol. 2010 Apr;8(4):296-307. doi: 10.1038/nrmicro2321. Review.


CpG-B oligodeoxynucleotides inhibit TLR-dependent and -independent induction of type I IFN in dendritic cells.

Liu YC, Gray RC, Hardy GA, Kuchtey J, Abbott DW, Emancipator SN, Harding CV.

J Immunol. 2010 Apr 1;184(7):3367-76. doi: 10.4049/jimmunol.0903079. Epub 2010 Feb 24.


Presenting exogenous antigen to T cells.

Harding CV, Ramachandra L.

Curr Protoc Immunol. 2010 Feb;Chapter 16:Unit 16.2. doi: 10.1002/0471142735.im1602s88.


Choosing and preparing antigen-presenting cells.

Harding CV, Canaday D, Ramachandra L.

Curr Protoc Immunol. 2010 Feb;Chapter 16:Unit 16.1. doi: 10.1002/0471142735.im1601s88.


Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling.

Mahon RN, Rojas RE, Fulton SA, Franko JL, Harding CV, Boom WH.

Infect Immun. 2009 Oct;77(10):4574-83. doi: 10.1128/IAI.00222-09. Epub 2009 Aug 3.


TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis.

Drage MG, Pecora ND, Hise AG, Febbraio M, Silverstein RL, Golenbock DT, Boom WH, Harding CV.

Cell Immunol. 2009;258(1):29-37. doi: 10.1016/j.cellimm.2009.03.008. Epub 2009 Apr 11.


P2X7 receptor-stimulated secretion of MHC class II-containing exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1.

Qu Y, Ramachandra L, Mohr S, Franchi L, Harding CV, Nunez G, Dubyak GR.

J Immunol. 2009 Apr 15;182(8):5052-62. doi: 10.4049/jimmunol.0802968.


Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression.

Hardy GA, Sieg SF, Rodriguez B, Jiang W, Asaad R, Lederman MM, Harding CV.

Blood. 2009 May 28;113(22):5497-505. doi: 10.1182/blood-2008-11-190231. Epub 2009 Mar 19.

Supplemental Content

Loading ...
Support Center